Abbott Laboratories Operating Income 2010-2024 | ABT
Abbott Laboratories annual/quarterly operating income history and growth rate from 2010 to 2024. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
- Abbott Laboratories operating income for the quarter ending March 31, 2024 was $1.386B, a 8.15% decline year-over-year.
- Abbott Laboratories operating income for the twelve months ending March 31, 2024 was $6.355B, a 8.68% decline year-over-year.
- Abbott Laboratories annual operating income for 2023 was $6.478B, a 22.53% decline from 2022.
- Abbott Laboratories annual operating income for 2022 was $8.362B, a 0.75% decline from 2021.
- Abbott Laboratories annual operating income for 2021 was $8.425B, a 57.27% increase from 2020.
| Abbott Laboratories Annual Operating Income (Millions of US $) |
|
|---|---|
| 2023 | $6,478 |
| 2022 | $8,362 |
| 2021 | $8,425 |
| 2020 | $5,357 |
| 2019 | $4,532 |
| 2018 | $3,650 |
| 2017 | $1,564 |
| 2016 | $3,026 |
| 2015 | $2,867 |
| 2014 | $2,599 |
| 2013 | $2,133 |
| 2012 | $1,360 |
| 2011 | $1,629 |
| 2010 | $6,088 |
| 2009 | $6,236 |
| Abbott Laboratories Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2024-03-31 | $1,386 |
| 2023-12-31 | $1,780 |
| 2023-09-30 | $1,647 |
| 2023-06-30 | $1,542 |
| 2023-03-31 | $1,509 |
| 2022-12-31 | $1,304 |
| 2022-09-30 | $1,770 |
| 2022-06-30 | $2,376 |
| 2022-03-31 | $2,912 |
| 2021-12-31 | $2,378 |
| 2021-09-30 | $2,546 |
| 2021-06-30 | $1,392 |
| 2021-03-31 | $2,109 |
| 2020-12-31 | $2,432 |
| 2020-09-30 | $1,495 |
| 2020-06-30 | $672 |
| 2020-03-31 | $758 |
| 2019-12-31 | $1,389 |
| 2019-09-30 | $1,198 |
| 2019-06-30 | $1,206 |
| 2019-03-31 | $739 |
| 2018-12-31 | $1,165 |
| 2018-09-30 | $995 |
| 2018-06-30 | $882 |
| 2018-03-31 | $608 |
| 2017-12-31 | $651 |
| 2017-09-30 | $769 |
| 2017-06-30 | $386 |
| 2017-03-31 | $-242 |
| 2016-12-31 | $789 |
| 2016-09-30 | $897 |
| 2016-06-30 | $816 |
| 2016-03-31 | $524 |
| 2015-12-31 | $815 |
| 2015-09-30 | $713 |
| 2015-06-30 | $729 |
| 2015-03-31 | $610 |
| 2014-12-31 | $829 |
| 2014-09-30 | $728 |
| 2014-06-30 | $677 |
| 2014-03-31 | $365 |
| 2013-12-31 | $418 |
| 2013-09-30 | $473 |
| 2013-06-30 | $627 |
| 2013-03-31 | $615 |
| 2012-12-31 | $-23 |
| 2012-09-30 | $310 |
| 2012-06-30 | $564 |
| 2012-03-31 | $509 |
| 2011-12-31 | $2,082 |
| 2011-09-30 | $595 |
| 2011-06-30 | $1,773 |
| 2011-03-31 | $1,301 |
| 2010-12-31 | $1,830 |
| 2010-09-30 | $1,181 |
| 2010-06-30 | $1,606 |
| 2010-03-31 | $1,470 |
| 2009-12-31 | $1,864 |
| 2009-09-30 | $1,640 |
| 2009-06-30 | $1,671 |
| 2009-03-31 | $1,061 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $180.765B | $40.109B |
| Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stryker (SYK) | United States | $129.618B | 31.05 |
| Boston Scientific (BSX) | United States | $112.981B | 35.99 |
| Medtronic (MDT) | Ireland | $100.927B | 15.11 |
| EssilorLuxottica (ESLOY) | France | $99.128B | 0.00 |
| Lonza Group Ag (LZAGY) | Switzerland | $40.585B | 0.00 |
| Haleon (HLN) | United Kingdom | $37.716B | 27.53 |
| ResMed (RMD) | United States | $28.121B | 26.40 |
| Terumo (TRUMY) | Japan | $24.403B | 34.46 |
| Koninklijke Philips (PHG) | Netherlands | $22.841B | 18.13 |
| Zimmer Biomet Holdings (ZBH) | United States | $22.328B | 14.26 |
| Baxter (BAX) | United States | $17.045B | 12.12 |
| Insulet (PODD) | United States | $14.134B | 62.67 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $10.833B | 0.00 |
| Demant (WILYY) | Denmark | $9.370B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $7.790B | 25.48 |
| BellRing Brands (BRBR) | United States | $7.453B | 35.06 |
| Lantheus Holdings (LNTH) | United States | $5.565B | 13.87 |
| GN Store Nord (GNNDY) | Denmark | $4.222B | 23.71 |
| Haemonetics (HAE) | United States | $4.215B | 20.79 |
| Perrigo (PRGO) | Ireland | $3.501B | 10.61 |
| Prestige Consumer Healthcare (PBH) | United States | $3.437B | 16.35 |
| Neogen (NEOG) | United States | $3.386B | 32.56 |
| ICU Medical (ICUI) | United States | $2.893B | 25.54 |
| Envista Holdings (NVST) | United States | $2.858B | 11.79 |
| TG Therapeutics (TGTX) | United States | $2.749B | 77.35 |
| Green Thumb Industries (GTBIF) | United States | $2.552B | 49.96 |
| Agios Pharmaceuticals (AGIO) | United States | $2.448B | 0.00 |
| QuidelOrtho (QDEL) | United States | $2.225B | 12.35 |
| LeMaitre Vascular (LMAT) | United States | $1.847B | 54.13 |
| Maravai LifeSciences Holdings (MRVI) | United States | $1.804B | 0.00 |
| Warby Parker (WRBY) | United States | $1.592B | 0.00 |
| InMode (INMD) | Israel | $1.532B | 8.14 |
| AdaptHealth (AHCO) | United States | $1.332B | 9.90 |
| Verano Holdings (VRNOF) | United States | $1.246B | 0.00 |
| AtriCure (ATRC) | United States | $1.084B | 0.00 |
| Owens & Minor (OMI) | United States | $1.033B | 9.00 |
| National Vision Holdings (EYE) | United States | $1.028B | 32.72 |
| BioLife Solutions (BLFS) | United States | $0.987B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.771B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.679B | 14.46 |
| Evolus (EOLS) | United States | $0.679B | 0.00 |
| PetIQ (PETQ) | United States | $0.656B | 21.21 |
| VAREX IMAGING (VREX) | United States | $0.602B | 14.16 |
| Surmodics (SRDX) | United States | $0.599B | 37.54 |
| Quanterix (QTRX) | United States | $0.506B | 0.00 |
| ZimVie (ZIMV) | United States | $0.498B | 42.44 |
| Canopy Growth (CGC) | Canada | $0.491B | 0.00 |
| Valneva SE (VALN) | France | $0.488B | 0.00 |
| Biote (BTMD) | United States | $0.463B | 10.67 |
| Jin Medical (ZJYL) | China | $0.403B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.394B | 0.00 |
| Cerus (CERS) | United States | $0.325B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.315B | 10.14 |
| Zynex (ZYXI) | United States | $0.296B | 40.52 |
| MacroGenics (MGNX) | United States | $0.266B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.254B | 25.19 |
| Aurora Cannabis (ACB) | Canada | $0.252B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.243B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.236B | 14.85 |
| Omeros (OMER) | United States | $0.235B | 0.00 |
| Ayr Wellness (AYRWF) | United States | $0.233B | 0.00 |
| High Tide (HITI) | Canada | $0.178B | 0.00 |
| Organigram Holdings (OGI) | Canada | $0.160B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.153B | 21.76 |
| Capricor Therapeutics (CAPR) | United States | $0.153B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.150B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.137B | 0.00 |
| Veru (VERU) | United States | $0.123B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.110B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.104B | 0.00 |
| Fonar (FONR) | United States | $0.101B | 10.26 |
| Brainsway (BWAY) | Israel | $0.101B | 0.00 |
| InterCure (INCR) | Israel | $0.092B | 15.46 |
| Cellectar Biosciences (CLRB) | United States | $0.090B | 0.00 |
| Eagle Pharmaceuticals (EGRX) | United States | $0.073B | 4.75 |
| MariMed (MRMD) | United States | $0.069B | 0.00 |
| Safety Shot (SHOT) | United States | $0.060B | 0.00 |
| Rockwell Medical (RMTI) | United States | $0.053B | 0.00 |
| Modular Medical (MODD) | United States | $0.051B | 0.00 |
| Zevia PBC (ZVIA) | United States | $0.049B | 0.00 |
| Bright Green (BGXX) | United States | $0.048B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.048B | 0.00 |
| Apyx Medical (APYX) | United States | $0.046B | 0.00 |
| United-Guardian (UG) | United States | $0.041B | 14.90 |
| Cytosorbents (CTSO) | United States | $0.038B | 0.00 |
| ImmuCell (ICCC) | United States | $0.038B | 0.00 |
| Exagen (XGN) | United States | $0.032B | 0.00 |
| Nephros (NEPH) | United States | $0.022B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.021B | 0.00 |
| Agape ATP (ATPC) | $0.016B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.016B | 0.00 |
| Flora Growth (FLGC) | United States | $0.013B | 0.00 |
| GUARDION HEALTH (GHSI) | United States | $0.013B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.012B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.011B | 0.00 |
| NeuroMetrix (NURO) | United States | $0.007B | 0.00 |
| FSD PHARMA (HUGE) | Canada | $0.007B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Leafly Holdings (LFLY) | United States | $0.005B | 0.00 |
| Sharps Technology (STSS) | United States | $0.004B | 0.00 |
| Senestech (SNES) | United States | $0.003B | 0.00 |
| Lucy Scientific Discovery (LSDI) | Canada | $0.001B | 0.00 |
| Akanda (AKAN) | United Kingdom | $0.001B | 0.00 |
| Smart For Life (SMFL) | United States | $0.000B | 0.00 |
| SNDL (SNDL) | Canada | $0.000B | 0.00 |